Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Priority to CU20100165ApriorityCriticalpatent/CU20100165A7/en
Publication of CU20100165A7publicationCriticalpatent/CU20100165A7/en
Un sistema de administración de drogas también usado como forma de dosificación unitaria que comprende una matriz de película delgada soluble en agua, en donde la matriz comprende: a) on copolímero de injerto polivinilacohol-poli-etilenglicol (copolímero de injerto PVA-PEG) como polímero de matriz soluble en agua; b) un ingrediente activo que es un esteroide en el cual las posiciones 6 y 7 de la estructura esteroide son ambas un residuo -CH2-; y la mencionada matriz de polímero tienen un espesor de menos de 300 microm.A drug delivery system also used as a unit dosage form comprising a water soluble thin film matrix, wherein the matrix comprises: a) on polyvinyl alcohol-poly-ethylene glycol graft copolymer (PVA-PEG graft copolymer) as water soluble matrix polymer; b) an active ingredient that is a steroid in which positions 6 and 7 of the steroid structure are both a residue -CH2-; and said polymer matrix have a thickness of less than 300 microm.
CU20100165A2010-08-132010-08-13
DRUG ADMINISTRATION SYSTEM WITH STABILIZING EFFECT
CU20100165A7
(en)
Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
Unit dosage form comprising a thin film matrix comprising a water soluble matrix polymer and 10 to 200 ug of estradiol, or a hydrate or an ester, with a thickness less than 300 um, useful in a physical condition. caused by insufficient endogenous levels of estrogens.